<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> patients harbor a single amino acid mutation (S252W) in fibroblast growth factor (FGF) receptor 2 (FGFR2), which leads to abnormal FGF/FGFR2 signaling </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that specific combinations of FGFs and <z:chebi fb="0" ids="18085">glycosaminoglycans</z:chebi> activate both alternative splice forms of the mutant but not of the <z:mp ids='MP_0002169'>wild-type</z:mp> FGF receptors </plain></SENT>
<SENT sid="2" pm="."><plain>More importantly, 2-O- and N-sulfated <z:chebi fb="0" ids="24500">heparan</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi>, prepared by a combined chemical and enzymatic synthesis, antagonized the over-activated FGFR2b (S252W) to basal levels at nanomolar concentrations </plain></SENT>
<SENT sid="3" pm="."><plain>These studies demonstrated that specific <z:chebi fb="0" ids="18085">glycosaminoglycans</z:chebi> could be useful in treating ligand-dependent FGFR signaling-related diseases, such as <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>